Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker‐Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: Results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–27.
Article
CAS
PubMed
Google Scholar
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: An overview. Ann Rheum Dis. 2002;61:iii8–iii18.
Article
PubMed Central
PubMed
Google Scholar
Özgül A, Peker F, Taskaynatan MA, Tan AK, Dinçer K, Kalyon TA. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol. 2006;25:168–74.
Article
PubMed
Google Scholar
Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med. 2002;346:1349–56.
Article
CAS
PubMed
Google Scholar
Brophy S, Davies H, Dennis MS, Cooksey R, Husain MJ, Irvine E, et al. Fatigue in ankylosing spondylitis: Treatment should focus on pain management. Sem Arthritis Rheum. 2013;42:361–7.
Article
Google Scholar
National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for ankylosing spondylitis. London: National Institute for Health and Clinical Excellence; 2008.
Google Scholar
National Institute for Health and Care Excellence. Final appraisal determination: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (including a review of TA143 and TA233). http://www.nice.org.uk/guidance/gid-tag355/resources/ankylosing-spondylitis-and-axial-spondyloarthritis-nonradiographic-adalimumab-etanercept-infliximab-and-golimumab-inc-rev-ta143-and-ta233-id694-final-appraisal-determination-document2 (2015). Accessed 8 October 2015.
Bartlett C, Doyal L, Ebrahim S, Ebrahim S, Davey P, Bachmann M, et al. The causes and effects of socio-demographic exclusion from clinical trials. Health Technol Assess. 2005;9:38.
Article
Google Scholar
Astern P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705–14.
Google Scholar
Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:1120–7.
Article
CAS
PubMed
Google Scholar
Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative UK-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ. 1979;2:1461–6.
Article
PubMed Central
CAS
PubMed
Google Scholar
Furst FE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, editors. Rheumatology, vol. Volume 3, Section 9. 2nd ed. London: Mosby; 1998. p. 1–10.
Google Scholar
Symmons DPM, Barrett EM, Bankhead CR, Scott DGL, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: Results from the Norfolk Arthritis Register. Rheumatol. 1994;33:735–9.
Article
CAS
Google Scholar
Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O’Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity. Arthritis Rheum. 2004;50:1734–9.
Article
PubMed
Google Scholar
Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: Prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007;34:696–705.
PubMed
Google Scholar
Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–89.
Article
PubMed
Google Scholar
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1–ii44.
PubMed
Google Scholar
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis: The Bath AS metrology index. J Rheumatol. 1994;21:1694–8.
CAS
PubMed
Google Scholar
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
CAS
PubMed
Google Scholar
Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8.
Article
PubMed
Google Scholar
Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Rheumatol. 1996;35:66–71.
Article
CAS
Google Scholar
Calin A, Garrett S, Whitelock H, Kennedy LC, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
CAS
PubMed
Google Scholar
Ware JE, Kosinki M, Keller SD. A 12 item short form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.
Article
PubMed
Google Scholar
Doward LC, Spoorenberg A, Cook SA, Whallet D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62:20–6.
Article
PubMed Central
CAS
PubMed
Google Scholar
EuroQoL Group. A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
Article
Google Scholar
Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147–53.
Article
CAS
PubMed
Google Scholar
Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41:313–21.
Article
CAS
PubMed
Google Scholar
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
Article
CAS
PubMed
Google Scholar
Reilly MC, Gooch K, Wong RL, Kupper H, Van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatol. 2010;49:812–9.
Article
Google Scholar
Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiologic studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38:1113–22.
Article
PubMed
Google Scholar
Department of Health. NHS reference costs. https://www.gov.uk/government/collections/nhs-reference-costs (2014). Accessed 14 September 2015.
Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.
Google Scholar
Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients in ankylosing spondylitis with and without TNF blockers: A systematic review and meta-analysis of randomised placeb-controlled trials. Ann Rheum Dis. 2010;69:1756–61.
Article
CAS
PubMed
Google Scholar
Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21:552–60.
Article
CAS
PubMed
Google Scholar
McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess. 2007;11(28):1–158.
Article
CAS
Google Scholar
Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration’s comments and concerns. Arthritis Rheumatol. 2014;66:2649–56.
Article
CAS
PubMed
Google Scholar
Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74:1087–93.
Article
PubMed Central
PubMed
Google Scholar
Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72:229–34.
Article
PubMed Central
CAS
PubMed
Google Scholar
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:1810–4.
Article
PubMed Central
CAS
PubMed
Google Scholar
Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:1831–4.
Article
PubMed Central
CAS
PubMed
Google Scholar
Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2012;64:1108–15.
CAS
Google Scholar
British Society for Rheumatology. British Society for Rheumatology Position Statement on biosimilar medicines (February 2015). http://www.rheumatology.org.uk/includes/documents/cm_docs/2015/b/bsr_biosimilars_position_statement_feb_2015.pdf (2015). Accessed 6 Oct 2015.